BioCentury
ARTICLE | Finance

Adopting Adaptimmune

Why investors preferred Adaptimmune's TCR platform to other T cell therapy cos

September 29, 2014 7:00 AM UTC

Adaptimmune Ltd. attracted its first institutional investors with the maturity of its engineered T cell receptor platform, which could access more and different targets than chimeric antigen receptor therapies.

New investor New Enterprise Associates led last week's $104 million round, joined by new investors OrbiMed Advisors, Wellington Management, Fidelity Biosciences, Foresite Capital, Ridgeback Capital, Novo A/S, QVT, Rock Springs Capital, venBio Select and Merlin Nexus. Returning investors included the University of Oxford and high net worth individuals...